ACIXF (Acarix AB) E10: $-0.08 (As of Mar. 2026)


ACIXF Acarix AB ACIXF
47 GF Score
Price $0.03
GF Value $0.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Acarix AB E10?

Acarix AB ACIXF 47 E10 is $-0.08 as of Mar. 2026. GuruFocus rates ACIXF with a GF Score™ of 47/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Acarix AB's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.001. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.08 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-24), Acarix AB's current stock price is $0.029. Acarix AB's E10 for the quarter that ended in Mar. 2026 was $-0.08. Acarix AB's Shiller PE Ratio of today is .


Acarix AB  (OTCPK:ACIXF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Acarix AB E10 Related Terms


Acarix AB E10 Historical Data

* Premium members only.

The historical data trend for Acarix AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB E10 Chart

Acarix AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.09

Acarix AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.08 -0.09 -0.09 -0.08

ACIXF vs ABT, SYK, MDT: E10 Comparison

For the Medical Devices subindustry, Acarix AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acarix AB Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Acarix AB's Shiller PE Ratio falls into.


ACIXF
47GF Score
Acarix AB ACIXF
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Acarix AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.001/133.3862*133.3862
=-0.001

Current CPI (Mar. 2026) = 133.3862.

Acarix AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.009 101.019 -0.012
201609 -0.125 101.138 -0.165
201612 -0.042 102.022 -0.055
201703 -0.008 102.022 -0.010
201706 -0.015 102.752 -0.019
201709 -0.018 103.279 -0.023
201712 -0.030 103.793 -0.039
201803 -0.019 103.962 -0.024
201806 -0.021 104.875 -0.027
201809 -0.028 105.679 -0.035
201812 -0.026 105.912 -0.033
201903 -0.040 105.886 -0.050
201906 -0.039 106.742 -0.049
201909 -0.039 107.214 -0.049
201912 -0.020 107.766 -0.025
202003 -0.016 106.563 -0.020
202006 -0.016 107.498 -0.020
202009 -0.010 107.635 -0.012
202012 -0.007 108.296 -0.009
202103 -0.008 108.360 -0.010
202106 -0.009 108.928 -0.011
202109 -0.008 110.338 -0.010
202112 -0.014 112.486 -0.017
202203 -0.006 114.825 -0.007
202206 -0.006 118.384 -0.007
202209 -0.007 122.296 -0.008
202212 -0.009 126.365 -0.010
202303 -0.004 127.042 -0.004
202306 -0.046 129.407 -0.047
202309 -0.004 130.224 -0.004
202312 -0.003 131.912 -0.003
202403 -0.002 132.205 -0.002
202406 -0.002 132.716 -0.002
202409 -0.002 132.304 -0.002
202412 -0.001 132.987 -0.001
202503 -0.001 132.825 -0.001
202506 -0.001 133.699 -0.001
202509 -0.001 133.482 -0.001
202512 -0.001 133.386 -0.001
202603 -0.001 133.386 -0.001

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.08 mean?
Acarix AB (ACIXF) has a E10 of $-0.08 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Acarix AB and its competitors.
Is Acarix AB's E10 too high?
Acarix AB's current E10 is $-0.08. Overall, Acarix AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's E10 compare to ABT and SYK?
Acarix AB's E10 of $-0.08 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Acarix AB and its competitors. Acarix AB's current E10 is $-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 45% above its estimated fair value. The current E10 is $-0.08. Acarix AB's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Acarix AB (ACIXF), the current E10 is $-0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (ACIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of $0.03 is trading 45% above its estimated GF Value™ of $0.02. GuruFocus considers Acarix AB to be Significantly Overvalued.

Key valuation signals for ACIXF:

  • E10: $-0.08
  • GF Value™: $0.02 vs. price of $0.03 (45% above fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Acarix AB Business Description

Other Exchanges ACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
47GF Score

Get the complete analysis for ACIXF

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price
$0.02
GF Value